eligibility_summary
Adults 18–84 with severe asthma (ERS/ATS 2014: high-dose ICS plus another controller). Longitudinal: uncontrolled (ACT<20 and/or ≥1 exacerbation in 6 mo), biologic‑naïve, with indication to start biologic (omalizumab/mepolizumab/benralizumab/dupilumab). Cross‑sectional: on one of these biologics ≥6 mo, controlled (ACT>20, no exacerbation 6 mo) or uncontrolled. Exclude: refusal, legal guardianship, non-steroid immunosuppressants, biologic for other use, no social security/state aid.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Observational study in severe asthma assessing how approved biologics affect neutrophil and eosinophil phenotypes/functions. Drugs: omalizumab (anti-IgE monoclonal antibody, binds free IgE to reduce FcεRI-mediated mast cell/basophil activation), mepolizumab (anti–IL‑5 monoclonal antibody, neutralizes IL‑5 to reduce eosinophil maturation/survival), benralizumab (anti–IL‑5Rα afucosylated monoclonal antibody, induces ADCC to deplete eosinophils/basophils), dupilumab (anti–IL‑4Rα monoclonal antibody, blocks IL‑4/IL‑13 signaling to suppress type‑2 inflammation). Targeted cells/pathways: eosinophils (IL‑5/IL‑5R axis), Th2 cytokines (IL‑4/IL‑13), IgE-mediated allergic pathway, study also profiles neutrophils and Th17-related inflammation (IL‑17, IL‑6, IL‑8, IL‑11, GM‑CSF), including NETs/ROS/proteases.